Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.

Leukemia - 1 Apr 2014

Chu J, Deng Y, Benson D M, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine S M, Zhang X, Caligiuri M A, Hofmeister C C, Yu J

Abstract excerpt

Multiple myeloma (MM) is an incurable hematological malignancy. Chimeric antigen receptor (CAR)-expressing T cells have been demonstrated successfully in the clinic to treat B-lymphoid malignancies. However, the potential utility of antigen-specific CAR-engineered natural-killer (NK) cells to treat MM has not been explored. In this study, we determined whether CS1, a surface protein that is highly expressed on MM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytotoxicity, Immunologic
Share to Genetic Engineering

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lentivirus

Share to Mice, Inbred NOD

Share to Multiple Myeloma

Share to Receptors, Antigen

Share to Receptors, Immunologic

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 24067492
DOI: 10.1038/leu.2013.279
PMCID: PMC3967004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.PMID 24067492Read ↗

A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple MyelomaSemantic proximity Read ↗

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple MyelomaSemantic proximity Read ↗

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read ↗

Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with independent signalling demonstrate efficacy and safety in preclinical models of Multiple MyelomaSemantic proximity Read ↗

Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells.Semantic proximity Read ↗

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.Semantic proximity Read ↗

A compound chimeric antigen receptor strategy for targeting multiple myelomaSemantic proximity Read ↗

Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myelomaSemantic proximity Read ↗

Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.Semantic proximity Read ↗

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cellsSemantic proximity Read ↗

Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.